Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Indication: Dabrafenib and trametinib for unresectable or metastatic solid tumors
Study: Open-label, nonrandomized, phase II basket study Unresectable or metastatic 36 anaplastic thyroid cancer patients Dabrafenib 150 mg x 2 /day plus trametinib 2 mg/day Efficacy: ORR: 56% (95% CI,
New Indication: Dabrafenib + trametinib for bRAF V600E mutant glioma
Study: Multicenter, international, phase 2 study Metastatic HER2-mutant NSCLC (refractory to standard treatment) Trastuzumab deruxtecan >= 6.4 mg per kilogram of body weight Efficacy: ORR: 55% (95% CI, 44 to